The First Part of This Inventory Deals About the State of the Research In

Total Page:16

File Type:pdf, Size:1020Kb

The First Part of This Inventory Deals About the State of the Research In Directory Institute Pathophysiology Circulatory system, Hemostasis, Metabolism & Pneumology, Dermatology, Nutrition Diabetes, Metabolism/Nutrition, Endocrinology Gastroenterology, Hepatology, Uro-Nephrology, Osteoarticular system - July 2018 - 1 Table of contents Introduction p 3 Research Teams Circulatory system p 12 Hemostasis p 74 Pneumology p 79 Dermatology p 100 Diabetes p 105 Metabolism/Nutrition p 123 Endocrinology p 197 Gastro-enterology p 216 Hepatology p 229 Uro-Nephrology p 237 Osteo-articular system p 250 2 Introduction 3 1 – Fields covered The life science Institute Pathophysiology, Metabolism & Nutrition (PMN) covers a wide spectrum of research in physiology, experimental medicine and human diseases. The fields covered include heart and vessels, lungs, endocrine organs, liver, kidney, skin, joints and bones, and organs involved in nutrient processing, from all aspects of nutrition, from the control of food intake and nutritional behavior to digestive processing, control of substrate use and storage. The diseases in question frequently show common biological mechanisms and often lack of suitable treatments designed on a pathophysiological basis. 2 – Major scientific challenges in biology and medicine Public health care challenges Among diseases within the PMN scope, cardiovascular, respiratory, metabolic and nutritional diseases with their devastating complications represent a major public health care challenge. Diabetes, hyperlipidemia, obesity, renal insufficiency lead to cardiovascular disease, the major cause of mortality in industrialized countries and usually develop in relation with atherosclerosis. Coronary artery disease, stroke and chronic heart failure are responsible for 75% of cardiovascular-related deaths. They represent 29% of deaths in France, almost equaling deaths due to cancer. Thrombotic diseases are very prevalent, arterial thrombosis (ischaemic diseases) and venous thrombosis (thrombo-embolic disease) are the world's leading cause of death. The prevalence of constitutional haemorrhagic diseases is limited, but their social and economic impact is significant, as in the case of haemophilia. Respiratory diseases (asthma, chronic obstructive pulmonary disease, COPD; pulmonary fibroses) affect millions of people in France and their incidence is increasing. COPD alone already represents the third-largest cause of death in Europe (sixth in the world). The prevalence of diabetes is 7.4% in France in the age range 20 to 79 (IDF 2015). The increasing prevalence of diabetes parallels that of obesity, which raised to 15.8% among men and 15.6% among women in France (age range 30 to 69, INVS 2013). Regarding the visceral obesity the prevalence reaches 41.6% and 48.5% respectively. Diabetes is among the leading causes of blindness, end stage renal disease, non-traumatic limb amputation in adults and coronary heart disease. Type 2 diabetes is a multifactorial disease that shows heterogeneity in many respects and is often a manifestation of a much broader underlying disorder often referred to as the metabolic syndrome, an operational paradigm that includes hyperinsulinaemia, dyslipidaemia, hypertension, visceral obesity, hypercoagulability and microalbuminuria. Metabolic syndrome also leads to various non-vascular complications, including steatohepatis, cirrhosis or arthrosis. The metabolic epidemics and its cardiovascular complications although world-wide have been most pronounced in non- European populations, as shown by studies from Native American and Canadian communities, Pacific and Indian Ocean island populations or populations throughout Asia. Paradoxically, malnutrition is also a major threat to global human health and survival. Recent estimates indicate that nutritional deficiencies account for 3 million child deaths each year in less- developed countries while progress toward designing effective life-saving interventions is currently hampered by serious gaps in our understanding of nutrient metabolism in the human. Denutrition is further observed in 40% of patients suffering from chronic diseases, in 30 to 50% of hospitalized patients of all pathologies and is an independent factor for morbidity/mortality. Overall, there is a need for an increased research effort focusing on nutrition and its disorders, including the interrelationship with the environment, the human microbiome, digestive physiology, nutritional behaviors or food security. Diseases of the bones and joints are also a concern for the French, particularly due to ageing of the population. On their own they represent half of chronic diseases in people over 65 and are a major cause of invalidity (arthrosis is the second largest handicap factor in men, the fourth in women). 4 Among the over 50s, one women in four and one man in eight will be affected by osteoporosis during their lives. Skin diseases include a proportion of allergic complaints (atopic dermatitis, contact eczema, occupational dermatoses, photo-allergies, urticaria and skin accidents due to oral administration of a drug (toxicodermatitis)) and a proportion of chronic inflammatory disorders (psoriasis, atopic dermatitis, pelada, etc.). Among this latter group, psoriasis, affects between two and three million people in France and is associated with a significant change in the quality of life, often leading to a severe social handicap. The impact of this dermatosis on the quality of life is as significant as that caused by asthma, diabetes or chronic cardiac ischaemic diseases. The social cost of psoriasis is therefore considerable. Ageing of the population is increasingly frequently accompanied by chronic vascular complaints of the lower limbs. Their treatment is complex and should be multi-disciplinary, ideally as part of a care network led by dermatologists specialised in the field of cicatrisation. Other diseases that are in the scope of the Institute are frequent and/or carry high morbidity/mortality rates. Basic and clinical research is required to progress in our understanding of the mechanisms involved in cardiac, vascular, respiratory, renal, endocrine, digestive, dermatologic and osteoarticular disorders. Scientific challenges Diseases implicating heart and vessels, lungs, endocrine tissues, kidney, liver, skin, bone and joints and the digestive tract, although organ-specific, cannot be considered independently of the numerous interactions with the whole organism and the environment. Transversal aspects of physiology and pathology will be emphasized within the scope of the PMN Institute. Underlying fundamental research and biological issues that need to be addressed correspondingly cover a large field of disciplines requiring strong links between institutional partners, as well as with industrial partners. All these diseases share: 1- an incomplete knowledge of the genes involved in their etiology, a situation which is rapidly changing thanks in particular to the new genomic approaches, 2- an insufficient basic knowledge of gene and protein functions in target organs as well as their interaction with the environment; 3- incomplete understanding of pathophysiological mechanisms of diseases expressed within corresponding tissues, i.e. of mechanisms of initiation and progression of disease processes; 4- the general insufficiency of available treatments and preventive strategies based on a better understanding of the mechanisms of common diseases; 5- the understudied strategies of cell therapy, which could benefit to many of these diseases; 6- the importance of discovering new biomarkers that would be useful for diagnostic, prognostic and treatment guidance. 1) Gene/protein-function studies in physiology and interactions with environment The availability of gene sequences encoding for molecules of unknown functions emphasizes the need for extensive gene-function studies and for the characterization of tissue distribution of newly identified genes. As part of this task, the development of new models to empower these studies is required. Other emphasis is required on development biology, on studies of ageing mechanisms, on comparative genomics with the goal of better understanding of human gene and protein functions, on integrative physiology to decipher signalling and metabolic pathways and interactions at the whole organism level, on the understanding of gene interactions and gene networks that impact on individual cell and tissue functions, on epigenetics and metagenomics to study gene interactions with the environment. The sequence of an increasing number of individual human genomes also paves the path toward in depth understanding of human gene and post- transcriptional diversity in cell, tissue and organ physiology. With few exceptions, the miRNA target genes and the mechanism of target suppression are currently unknown because reliable experimental methods for comprehensively identifying the miRNA targets have yet to be developed. 5 2) Disease-initiating mechanisms and mechanisms of disease progression in common diseases. Mechanisms that trigger destructive processes within target tissues are seldom identified. Other than certain rare monogenic diseases involving key genes in cell function, common diseases usually develop on a multigenic susceptibility background associating “normal” gene variants, often affecting quantitative traits (intermediate phenotypes) that contribute to the clinical phenotype observed, most often interacting with environmental factors as part of a multifactorial process. As triggering factors remain elusive in most cases, new hypotheses
Recommended publications
  • Processing of Progranulin Into Granulins Involves Multiple Lysosomal Proteases and Is Affected in Frontotemporal Lobar Degeneration
    Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration Swetha Mohan University of California San Francisco Paul J. Sampognaro University of California San Francisco Andrea R. Argouarch University of California San Francisco Jason C. Maynard University of California San Francisco Anand Patwardhan University of California San Francisco Emma C. Courtney University of California San Francisco Amanda Mason University of California San Francisco Kathy H. Li University of California San Francisco William W. Seeley University of California San Francisco Bruce L. Miller University of California San Francisco Alma Burlingame University of California San Francisco Mathew P. Jacobson University of California San Francisco Aimee Kao ( [email protected] ) University of California San Francisco https://orcid.org/0000-0002-7686-7968 Research article Keywords: Progranulin, granulin, frontotemporal lobar degeneration, lysosome, protease, pH, asparagine endopeptidase Page 1/31 Posted Date: July 29th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-44128/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published at Molecular Neurodegeneration on August 3rd, 2021. See the published version at https://doi.org/10.1186/s13024-021-00472-1. Page 2/31 Abstract Background - Progranulin loss-of-function mutations are linked to frontotemporal lobar degeneration with TDP-43 positive inclusions (FTLD-TDP-Pgrn). Progranulin (PGRN) is an intracellular and secreted pro- protein that is proteolytically cleaved into individual granulin peptides, which are increasingly thought to contribute to FTLD-TDP-Pgrn disease pathophysiology. Intracellular PGRN is processed into granulins in the endo-lysosomal compartments.
    [Show full text]
  • AIBA Youth World Boxing Championships Yerevan 2012 Athletes Biographies
    AIBA Youth World Boxing Championships Yerevan 2012 Athletes Biographies 49KG – HAYRIK NAZARYAN – ARMENIA (ARM) Date Of Birth : 30/08/1995 Club : Working Shift Sport Company Coach : Marat Karoyan Residence : Yerevan Number of bouts : 60 Began boxing : 2002 2012 – Klichko Brothers Youth Tournament (Berdichev, UKR) 6th place – 49KG Lost to Sultan Abduraimov (KAZ) 12:3 in the quarter-final; Won against Danilo Pleshkov (UKR) AB 2nd round in the first preliminary round 2012 – Armenian Youth National Championships 1st place – 49KG Won against Andranik Peleshyan (ARM) by points in the final; Won against Taron Petrosyan (ARM) by points in the semi-final 2012 – Pavlyukov Youth Memorial Tournament (Anapa, RUS) 7th place – 49KG Lost to Keith Flavin (IRL) 30:6 in the quarter-final 2011 – AIBA Junior World Championships (Astana, KAZ) 7th place – 46KG Lost to Georgian Tudor (ROM) 15:14 in the quarter-final; Won against Dmitriy Asanov (BLR) 22:14 in the first preliminary round 2011 – European Junior Championships (Keszthely, HUN) 5th place – 46KG Lost to Timur Pirdamov (RUS) 17:4 in the quarter-final; Won against Zsolt Csonka (HUN) RSC 2nd round in the first preliminary round 2011 – Armenian Junior National Championships 1st place – 46KG 49KG – ROBERT TRIGG – AUSTRALIA (AUS) Date Of Birth : 03/01/1994 Place Of Birth : Mount Gambier Height : 154cm Club : Mt. Gambier Boxing Club Coach : Colin Cassidy Region : South Australia Began boxing : 2010 2012 – Oceanian Youth Championships (Papeete, TAH) 1st place – 49KG Won against Martin Dexon (NRU) by points
    [Show full text]
  • Esomeprazole Inhibits the Lysosomal Cysteine Protease Legumain to Prevent Cancer Metastasis
    Investigational New Drugs https://doi.org/10.1007/s10637-020-01011-3 PRECLINICAL STUDIES Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis Tian Zhao1 & Yujie Liu1 & Yanfei Hao1 & Wei Zhang1 & Li Tao1 & Dong Wang1 & Yuyin Li1 & Zhenxing Liu1 & Edward A McKenzie2 & Qing Zhao1 & Aipo Diao1 Received: 17 August 2020 /Accepted: 21 September 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020 Summary Legumain is a newly discovered lysosomal cysteine protease that can cleave asparagine bonds and plays crucial roles in regulating immunity and cancer metastasis. Legumain has been shown to be highly expressed in various solid tumors, within the tumor microenvironment and its levels are directly related to tumor metastasis and poor prognosis. Therefore, legumain presents as a potential cancer therapeutic drug target. In this study, we have identified esomeprazole and omeprazole as novel legumain small molecule inhibitors by screening an FDA approved-drug library. These compounds inhibited enzyme activity of both recombinant and endog- enous legumain proteins with esomeprazole displaying the highest inhibitory effect. Further molecular docking analysis also indicated that esomeprazole, the S- form of omeprazole had the most stable binding to legumain protein compared to R-omeprazole. Transwell assay data showed that esomeprazole and omeprazole reduced MDA-MB-231 breast cancer cell invasion without effecting cell viability. Moreover, an in vivo orthotopic transplantation nude mouse model study showed that esomeprazole reduced lung metastasis of MDA-MB-231 breast cancer cells. These results indicated that esomeprazole has the exciting potential to be used in anti-cancer therapy by preventing cancer metastasis via the inhibition of legumain enzyme activity.
    [Show full text]
  • The Orexins and Appetitive Motivation in the Rat Shaun Khoo a Thesis In
    The orexins and appetitive motivation in the rat Shaun Khoo A thesis in fulfillment of the requirements for the degree of Doctor of Philosophy School of Psychology Faculty of Science July 2017 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Khoo First name: Shaun Other name/s: Yon-Seng Abbreviation for degree as given in the University calendar: PhD School: Psychology Faculty: Science Title: The orexins and appetitive motivation in the rat Abstract 350 words maximum: (PLEASE TYPE) Addiction is a chronic relapsing disorder characterised by compulsive drug seeking that persists despite adverse consequences. One popular, and widely heralded therapeutic target, is the orexin system, a hypothalamic neuropeptide system involved in arousal, appetite and reward. The motivational activator theory, the first coherent account of orexin’s role in appetitive motivation, predicts that orexin contributes to appetitive behaviour, including drug seeking, when the reinforcer is highly salient, available under a high unit-cost, or when reward seeking cue- driven. The present study used the dual orexin receptor antagonist, TCS 1102, a commercially available compound related to the clinically approved insomnia drug, suvorexant. TCS 1102 was administered intracerebroventricularly to rats trained to self-administer food, 4% alcohol beer or intravenous nicotine in a variety of self-administration and relapse-like paradigms. While TCS 1102 was able to reduce orexin-A-induced increases in consumption of normal grain pellets, it did not affect FR1, FR5, or FR10 self-administration of palatable food or cue+prime reinstatement of palatable food seeking. Orexin neuron activation measured by c-Fos/orexin-A immunohistochemistry showed that while orexin neurons were robustly recruited under behavioural testing conditions, there was no specific activation of these neurons during cue-induced reinstatement.
    [Show full text]
  • Hypoxic-Induced Truncation of Voltage-Dependent Anion Channel 1 Is Mediated by Both Asparagine Endopeptidase and Calpain 1 Activities
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 16), pp: 12825-12841 Research Paper Hypoxic-induced truncation of voltage-dependent anion channel 1 is mediated by both asparagine endopeptidase and calpain 1 activities Hadas Pahima1,*, Simona Reina2,3,*, Noa Tadmor1,*, Daniella Dadon-Klein1,*, Anna Shteinfer-Kuzmine1, Nathalie M. Mazure4,5, Vito De Pinto2 and Varda Shoshan- Barmatz1 1Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel 2Department of Biomedicine and Biotechnology, University of Catania and National Institute for Biomembranes and Biosystems, Section of Catania, Catania 95125, Italy 3Department of Biological, Geological and Environmental Sciences, University of Catania, Catania 95125, Italy 4Institute for Research on Cancer and Aging of Nice, University of Nice Sophia-Antipolis, Centre Antoine Lacassagne, Nice 06189, France 5Present address: INSERM U1065, C3M, Nice 06204, France *These authors contributed equally to this work Correspondence to: Varda Shoshan-Barmatz, email: [email protected] Keywords: asparagine endopeptidase; calpain; hypoxia; VDAC1 Abbreviations: AEP: asparagine endopeptidase; VDAC1: voltage-dependent anion channel 1 Received: October 09, 2017 Accepted: January 25, 2018 Published: January 31, 2018 Copyright: Pahima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT The voltage-dependent anion channel 1 (VDAC1), an outer mitochondria membrane (OMM) protein, serves as a mitochondrial gatekeeper, mediating the transport of nucleotides, Ca2+ and other metabolites across the OMM.
    [Show full text]
  • Hear T Failure 2016
    B:160 mm T:150 mm S:130 mm NOW APPROVED1 NOW APPROVED IN THE EU* FLORENCE B:220 mm T:210 mm T:210 Final S:190 mm 2016 Programme FAILURE FAILURE VISIT BOOTH D10 TO LEARN MORE HEART Please see Summary of Product Characteristics at Booth D10. This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions. References: 1. Marketing authorization granted by the European Commission on 19 November 2015. Detailed information on this medicinal product, including the SmPC, is available on the website of the European Medicines Agency http://www.ema.europa.eu. 2. Roversi S, Tonelli R, Fabbri LM. Breakthroughs in internal and respiratory medicine. Lancet. 2015;3(8):600-602. ©2016 Novartis Pharma AG, CH-4002 Basel March 2016 GLCM/LCZ/0112 Promotional material submitted to AIFA on 13/04/2016. Printed in April 2016. 10522727_ESC_FinalPrgrm_M3.indd 1 4/6/16 11:36 AM PREPARED BY FCB Releasing as: PDFX1a Production: Barbara Grant x3946 Job #: 10522727 Colors: 4C AD: Kim Youri x2342 Client: Novartis Flat Size: 150mm w x 210mm h AE: Miquel Valiente Product: Entresto Bleed: 5mm all sides Producer: Kelli Currie Client Code: GLCM/LCZ/0112 Trim: 150mm w x 210mm h QC: L.Powell Date: April 6, 2016 11:35 AM Safety: 130mm w x 190mm h Digital Artist: gh, CL, CL Add’l Info: Proof: M3 M3 Spellcheck: Frank Episale FR Spellcheck: Path: PrePress:Novartis:LCZ696:10522727:10522727_ESC_FinalPrgrm_M3 4C Final Programme Ad Version 1 BUILDING FLOOR PLAN Congress organised by the Heart Failure association
    [Show full text]
  • 1 Sam Roberts 2 Swamishishu Videhanand 3 Alan Barrett 4 Irene
    1 Sam Roberts 2 swamishishu videhanand 3 Alan Barrett 4 Irene Mitchell 5 Tim Foggin 6 Francis Duffy 7 Nick Canever 8 Franklin Hall 9 Gudrun Wiedemann 10 Cath Dolman 11 Saul Palmer 12 Pat Thompson 13 Caroline De Vere 14 Jane Mortimer 15 Moritz Koenig 16 Kenneth Thomas 17 Tony Brand 18 Ray Harrowing 19 Andrew Cowley 20 A Winser 21 Andree Dignon 22 Annette Patterson 23 amanda healy 24 Adam Buckle 25 Anthony Kay 26 Adrian Lea 27 Alison Leslie 28 Alison Francis 29 Alan Mawer 30 Andrew MORLEY 31 Anita Morling 32 Audrey Rawlins 33 Alex House 34 Alan Dawson 35 Tiberiu Somiay 36 Adrian Treacher 37 Andrew Deacon 38 Alison Griffin 39 Anna muszynska 40 Aaron Davidson 41 Aaron Burr-Society 42 Rosemary Talbot 43 John Hodgson 44 Abas Ali 45 Abbie W 46 Abby Bentham 47 Abby Park 48 David Harvey 49 Abelardo Clariana-Piga 50 ( one name only) Abercrombie 51 E Parry 52 Andre Berly 53 Nicola Hetherington 54 Abigail Cameron 55 Alan Bignell 56 abi sheriden 57 Maria Antonia Bogonez 58 Adina Borta 59 Abby Wilson 60 Douglas Johnston 61 Margaret Whitson 62 Anthony Cartlidge 63 Anne Clarke 64 Keeley Swan 65 Elisabete Silva 66 Anthony Baker 67 Ann Cockerton 68 Ioan Clain 69 Graziano Siciliano 70 Adam Tucker 71 Adam Britton 72 Adam Harding 73 Jenny Adams 74 Adam Stuart 75 Adam Green 76 Adam Davies 77 Adrian Andronache 78 Adele Litherland 79 Niculae Adela 80 Adele May 81 adina pop 82 Anthony Hill 83 Adjowa Amegadje 84 adam zamojski 85 Adrian Peters 86 adrian McTiernan 87 Adrian Denning 88 Adrian Loram 89 Adrian Henriques 90 A Baltaretu 91 Boloveschi Adriana 92 Adrian
    [Show full text]
  • This Plea Is Not a Ploy to Get More Money to an Underfinanced Sector
    --------------------- Gentiana Rosetti Maura Menegatti Franca Camurato Straumann Mai-Britt Schultz Annemie Geerts Doru Jijian Drevariuc Pepa Peneva Barbara Minden Sandro Novosel Mircea Martin Doris Funi Pedro Biscaia Jean-Franois Noville Adina Popescu Natalia Boiadjieva Pyne Frederick Laura Cockett Francisca Van Der Glas Jesper Harvest Marina Torres Naveira Giorgio Baracco Basma El Husseiny Lynn Caroline Brker Louise Blackwell Leslika Iacovidou Ludmila Szewczuk Xenophon Kelsey Renata Zeciene Menndez Agata Cis Silke Kirchhof Antonia Milcheva Elsa Proudhon Barruetabea Dagmar Gester Sophie Bugnon Mathias Lindner Andrew Mac Namara SIGNED BY Zoran Petrovski Cludio Silva Carfagno Jordi Roch Livia Amabilino Claudia Meschiari Elena Silvestri Gioele Pagliaccia Colimard Louise Mihai Iancu Tamara Orozco Ritchie Robertson Caroline Strubbe Stphane Olivier Eliane Bots Florent Perrin Frederick Lamothe Alexandre Andrea Wiarda Robert Julian Kindred Jaume Nadal Nina Jukic Gisela Weimann Mihon Niculescu Laura Alexandra Timofte Nicos Iacovides Maialen Gredilla Boujraf Farida Denise Hennessy-Mills Adolfo Domingo Ouedraogo Antoine D Ivan Gluevi Dilyana Daneva Milena Stagni Fran Mazon Ermis Theodorakis Daniela Demalde’ Adrien Godard Stuart Gill --------------------- Kliment Poposki Maja Kraigher Roger Christmann Andrea-Nartano Anton Merks Katleen Schueremans Daniela Esposito Antoni Donchev Lucy Healy-Kelly Gligor Horia Fernando De Torres Olinka Vitica Vistica Pedro Arroyo Nicolas Ancion Sarunas Surblys Diana Battisti Flesch Eloi Miklos Ambrozy Ian Beavis Mbe
    [Show full text]
  • Families and Clans of Cysteine Peptidases
    Families and clans of eysteine peptidases Alan J. Barrett* and Neil D. Rawlings Peptidase Laboratory. Department of Immunology, The Babraham Institute, Cambridge CB2 4AT,, UK. Summary The known cysteine peptidases have been classified into 35 sequence families. We argue that these have arisen from at least five separate evolutionary origins, each of which is represented by a set of one or more modern-day families, termed a clan. Clan CA is the largest, containing the papain family, C1, and others with the Cys/His catalytic dyad. Clan CB (His/Cys dyad) contains enzymes from RNA viruses that are distantly related to chymotrypsin. The peptidases of clan CC are also from RNA viruses, but have papain-like Cys/His catalytic sites. Clans CD and CE contain only one family each, those of interleukin-ll3-converting enz3wne and adenovirus L3 proteinase, respectively. A few families cannot yet be assigned to clans. In view of the number of separate origins of enzymes of this type, one should be cautious in generalising about the catalytic mechanisms and other properties of cysteine peptidases as a whole. In contrast, it may be safer to gener- alise for enzymes within a single family or clan. Introduction Peptidases in which the thiol group of a cysteine residue serves as the nucleophile in catalysis are defined as cysteine peptidases. In all the cysteine peptidases discovered so far, the activity depends upon a catalytic dyad, the second member of which is a histidine residue acting as a general base. The majority of cysteine peptidases are endopeptidases, but some act additionally or exclusively as exopeptidases.
    [Show full text]
  • The Role of P66shca-TLR9 Signaling in Myocardial Remodeling and Innate Immune Responses
    The role of p66ShcA-TLR9 signaling in myocardial remodeling and innate immune responses Thesis for the degree of Philosophiae Doctor (Ph.D.) Anton Baysa, M.D. Division of Physiology Department of Molecular Medicine Institute of Basic Medical Science Faculty of Medicine University of Oslo 2020 © Anton Baysa, 2020 Series of dissertations submitted to the Faculty of Medicine, University of Oslo ISBN 978-82-8377-746-8 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Cover: Hanne Baadsgaard Utigard. Print production: Reprosentralen, University of Oslo. Table of Contents Acknowledgements ............................................................................................... 1 List of included papers .......................................................................................... 3 Selected abbreviations........................................................................................... 4 General introduction ............................................................................................. 6 Clinical perspectives .............................................................................................................. 6 Ischemic heart disease: Global and national status ........................................................... 6 Ischemic heart disease: Emerging trends and therapy limitations .................................... 6 Ischemic heart disease: Anti-inflammatory treatment .......................................................
    [Show full text]
  • Delta-Secretase Cleaves Amyloid Precursor Protein and Regulates the Pathogenesis in Alzheimer’S Disease
    ARTICLE Received 11 Mar 2015 | Accepted 25 Sep 2015 | Published 9 Nov 2015 DOI: 10.1038/ncomms9762 OPEN Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease Zhentao Zhang1,2, Mingke Song3, Xia Liu1, Seong Su Kang1, Duc M. Duong4,5, Nicholas T. Seyfried4,5, Xuebing Cao6, Liming Cheng7, Yi E. Sun7,8, Shan Ping Yu3, Jianping Jia9, Allan I. Levey4 & Keqiang Ye1 The age-dependent deposition of amyloid-b peptides, derived from amyloid precursor protein (APP), is a neuropathological hallmark of Alzheimer’s disease (AD). Despite age being the greatest risk factor for AD, the molecular mechanisms linking ageing to APP processing are unknown. Here we show that asparagine endopeptidase (AEP), a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing. AEP cleaves APP at N373 and N585 residues, selectively influencing the amyloidogenic fragmentation of APP. AEP is activated in normal mice in an age-dependent manner, and is strongly activated in 5XFAD transgenic mouse model and human AD brains. Deletion of AEP from 5XFAD or APP/PS1 mice decreases senile plaque formation, ameliorates synapse loss, elevates long-term potentiation and protects memory. Blockade of APP cleavage by AEP in mice alleviates pathological and behavioural deficits. Thus, AEP acts as a d-secretase, contributing to the age-dependent pathogenic mechanisms in AD. 1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA. 2 Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 3 Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
    [Show full text]
  • Edital De Notificação Detran/Pr- 2014Not005-Cl A
    EDITAL DE NOTIFICAÇÃO DETRAN/PR- 2014NOT005-CL A Comissão de Leilão do DETRAN/PR, nomeada pela Portaria N.º 449/13- DG, atendendo ao disposto no artigo 5º da Resolução 331/2009 Contran, do dia 14 de Agosto de 2009 e Resolução 449/2013 Contran, do dia 25 de Julho de 2013. Notifica aos interessados, bem como os Agentes Financeiros / Bancos e pessoas detentoras de reserva de Domínio, adiante relacionados nos anexos deste Edital, cujos veículos foram objeto de apreensão e encontram-se recolhidos aos pátios de veículos da; 1ª CIRETRAN na cidade de CURITIBA, situado na AV. VITOR FERREIRA DO AMARAL, Nº 2940, CAPÃO DA IMBUIA, telefone (41) 3361-1137, CEP 82.800-900; 1º BPM- 1ªCIA na cidade de PONTA GROSSA, situado na RUA PRF. CARDOSO FONTES, Nº985, RONDA, telefone (42) 3222-6677, CEP 84050-550; 9º BPM-1ªCIA na cidade de GUARATUBA, situado na RUA CUBATÃO, Nº123, CENTRO, telefone (41) 3442-6893, CEP 83280-000; 9ºBPM-1ªCIA na cidade de PARANAGUÁ, situado na RUA DOMINGOS PENEDA, Nº2001, SÃO VICENTE, telefone, CEP 83209-340; 2ª CIA INDEPENDENTE na cidade de UNIÃO DA VITÓRIA, situado na RUA ALEXANDRE SCHELENN, S/N, SÃO BASILIO MAGNO, telefone (42) 3523-1220, CEP 84.600-000; 5ª CIRETRAN na cidade de PATO BRANCO, situado na RUA ARGENTINA, Nº888, JARDIM DAS AMÉRICAS, telefone (46) 3225-3132, CEP 85.501-000; 6ª CIRETRAN na cidade de GUARAPUAVA, situado na AV. SEBASTIÃO DE CAMARGO RIBAS, Nº131, BOM SUCESSO, telefone (42) 3624-1600, CEP 85.060-340; 6ºBPM- 1ªCIA na cidade de CASCAVEL, situado na RUA GALIBIS, S/N, CENTRO, telefone (45) 226-8085, CEP 85.420-000; 8ª CIRETRAN na cidade de CAMPO MOURÃO, situado na RUA NEY BRAGA, S/N, JD.
    [Show full text]